300 institutions hold shares in Pacific Biosciences of California Inc. (PACB), with 4.7M shares held by insiders accounting for 2.43% while institutional investors hold 101.75% of the company’s shares. The shares outstanding are 186.16M, and float is at 180.45M with Short Float at 6.36%. Institutions hold 99.27% of the Float.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
The top institutional shareholder in the company is ARK Investment Management, LLC with over 28.5 million shares valued at $739.41 million. The investor’s holdings represent 14.76% of the PACB Shares outstanding. As of Dec 30, 2020, the second largest holder is Blackrock Inc. with 15.12 million shares valued at $392.1 million to account for 7.83% of the shares outstanding. The other top investors are Vanguard Group, Inc. (The) which holds 14.32 million shares representing 7.42% and valued at over $371.47 million, while Jackson Square Partners, LLC holds 6.98% of the shares totaling 13.47 million with a market value of $349.53 million.
Pacific Biosciences of California Inc. (NASDAQ: PACB) is 25.48% higher on its value in year-to-date trading and has touched a low of $2.66 and a high of $53.69 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The PACB stock was last observed hovering at around $35.50 in the last trading session, with the day’s loss setting it -2.95% off its average median price target of $48.00 for the next 12 months. It is also 47.5% off the consensus price target high of $62.00 offered by 5 analysts, but current levels are 27.67% higher than the price target low of $45.00 for the same period.
Currently trading at $32.55, the stock is -0.73% and -7.40% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 2.86 million and changing -8.31% at the moment leaves the stock 74.86% off its SMA200. PACB registered 992.28% gain for a year compared to 6-month gain of 155.49%. The firm has a 50-day simple moving average (SMA 50) of $33.94 and a 200-day simple moving average (SMA200) of $24.72.
The stock witnessed a 18.93% loss in the last 1 month and extending the period to 3 months gives it a 16.21%, and is 8.68% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 9.05% over the week and 9.84% over the month.
Pacific Biosciences of California Inc. (PACB) has around 412 employees, a market worth around $6.19B and $78.90M in sales. Current P/E ratio is 664.29. Profit margin for the company is 37.30%. Distance from 52-week low is 1123.68% and -39.37% from its 52-week high. The company has generated returns on investments over the last 12 months (8.20%).
Pacific Biosciences of California Inc. (PACB) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Pacific Biosciences of California Inc. (PACB) is a “Overweight”. 5 analysts offering their recommendations for the stock have an average rating of 2.40, where 2 rate it as a Hold and 0 think it is a “Overweight”. 3 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Pacific Biosciences of California Inc. is expected to release its quarterly report on 08/05/2021 and quarterly earnings per share for the current quarter are estimated at -$0.45 with sales reaching $25.67M over the same period.The EPS is expected to grow by 130.50% this year, but quarterly earnings will post 67.00% year-over-year. Quarterly sales are estimated to grow 64.60% in year-over-year returns.
Pacific Biosciences of California Inc. (PACB) Insider Activity
A total of 112 insider transactions have happened at Pacific Biosciences of California Inc. (PACB) in the last six months, with sales accounting for 63 and purchases happening 49 times. The most recent transaction is an insider sale by Hunkapiller Michael, the company’s Director. SEC filings show that Hunkapiller Michael sold 234,246 shares of the company’s common stock on Feb 26 at a price of $31.02 per share for a total of $7.27 million. Following the sale, the insider now owns 0.85 million shares.
Pacific Biosciences of California Inc. disclosed in a document filed with the SEC on Feb 25 that Hunkapiller Michael (Director) sold a total of 339,377 shares of the company’s common stock. The trade occurred on Feb 25 and was made at $32.33 per share for $10.97 million. Following the transaction, the insider now directly holds 0.85 million shares of the PACB stock.
Still, SEC filings show that on Feb 24, Hunkapiller Michael (Director) disposed off 266,427 shares at an average price of $36.80 for $9.81 million. The insider now directly holds 848,405 shares of Pacific Biosciences of California Inc. (PACB).
Pacific Biosciences of California Inc. (PACB): Who are the competitors?
The company’s main competitors (and peers) include Thermo Fisher Scientific Inc. (TMO) that is trading 53.41% up over the past 12 months and Fluidigm Corporation (FLDM) that is 124.88% higher over the same period. Illumina Inc. (ILMN) is 44.08% up on the 1-year trading charts. Short interest in the company’s stock has fallen -18.13% from the last report on Mar 14, 2021 to stand at a total of 11.47 million short shares sold with a short interest ratio of 2.09.